Results from the pivotal CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) study, evaluating canagliflozin for type 2 diabetes, were published on 2013-01-01. This publication detailed the 52-week efficacy and safety of canagliflozin compared to glimepiride in patients whose type 2 diabetes was inadequately controlled with metformin.
Background
The CANTATA-SU study investigated canagliflozin in patients with type 2 diabetes who had inadequate glycemic control despite treatment with metformin. Canagliflozin was explored as an add-on therapy, with glimepiride serving as the comparator. This comparison is clinically relevant as glimepiride is a commonly used sulfonylurea in this patient population.
Trial design
The CANTATA-SU study was designed to compare canagliflozin directly against glimepiride over a 52-week period. Both treatments were administered as add-on therapies to patients already receiving metformin. The study population included individuals with type 2 diabetes who had not achieved their glycemic targets with metformin alone. The primary objective was to assess the long-term efficacy and safety of canagliflozin in this specific patient group.
What this means
The publication of the 52-week results from the CANTATA-SU study provides important data for clinicians treating patients with type 2 diabetes. These findings offer a direct, long-term comparison of canagliflozin's efficacy and safety against glimepiride when both are used as add-on treatments to metformin. This information is crucial for making informed decisions regarding therapeutic strategies for patients whose glycemic control is insufficient with metformin alone, helping to position canagliflozin within current treatment paradigms.
Source
The information regarding these pivotal trial results was published on 2013-01-01. The study, titled "Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results fr", is accessible through PubMed, hosted at pubmed.ncbi.nlm.nih.gov. This publication provides the detailed findings of the CANTATA-SU trial, which is identified by PubMed ID 23850055.